Confidentiality and Publications. 11.1 As used in this Agreement, the term “
Confidentiality and Publications. 15.1 The Parties, their Affiliates and their respective directors, officers, employees, officers and consultants shall keep and maintain any Confidential Information supplied by the other Party during the term of this Agreement strictly confidential. The confidentiality obligations contained in this Agreement shall not apply to the extent that such Confidential Information is:
Confidentiality and Publications. (a) Each Team Member undertakes to keep confidential and not to disclose or use (other than for the furtherance of the Project) any Project Technology or BioLine Confidential Information to any person or entity other than a fellow Team Member, an employee of BIRAD, or an employee, officer or director of BioLine, except and to the extent that s/he is instructed or authorized to do so by BIRAD. This obligation of confidentiality does not apply to any portion of the Project Technology that is in the public domain (other than through the fault of such Team Member), nor does it apply to information included in scientific publications that have been approved by BIRAD prior to publication. "BioLine Confidential Information" means any scientific, technical, trade or business information relating to the Sponsored Research designated as confidential or which otherwise should reasonably be construed under the circumstances as being confidential disclosed by or on behalf of BioLine to a Team Member, except to the extent such information: (i) was known to such Team Member at the time it was disclosed, other than by previous disclosure by or on behalf of BioLine, as evidenced by such Team Member's written records at the time of disclosure; (ii) is at the time of disclosure or later becomes publicly known under circumstances involving no breach of this Letter; (iii) is lawfully and in good faith made available to the Team Member by a third party who is not subject to obligations of confidentiality to BioLine or BIRAD with respect to such information; or (iv) is independently developed by the Team Member without the use of or reference to BioLine Confidential Information, as demonstrated by documentary evidence.
Confidentiality and Publications. The Parties to this Agreement shall ensure that information supplied to or deriving from the Research is exchanged between themselves on a strictly confidential basis. Both Parties recognise that as required by QMUL’s legal status as an “Exempt Charity” and by its own statutes and regulations, the results of the Research shall be publishable in accordance with normal academic practice, and agree that any thesis written by staff or students of QMUL undertaking the Research shall be submitted in accordance with the QMUL’s regulations for higher degrees. In addition, the results of the Research shall be kept confidential to the extent necessary to protect the potential commercial value of any patentable inventions or other intellectual property rights generated during the Research, and any publication or disclosure of the results of the Research by a Party shall not include any of the other Party’s Confidential Information. Each Party shall send the other Party a draft of all intended publications in advance of publication for it to review them for the possible inclusion of any such Confidential Information. Each Party shall review any such proposed publications sent to it by the other Party within a period of 30 working days of their receipt and notify the other Party if a proposed publication contains any of its Confidential Information within the review period. In such an event, the Party wishing to make the publication shall delete, adapt or genericise any such Confidential Information prior to the publication being made, as agreed with other Party at the other Party’s discretion. QMUL shall acknowledge the support received from <<Contractor>> in any publications arising from this Agreement, unless requested to the contrary by <<Contractor>>. The obligations in clause 4.2 above shall not apply to data or information which the Receiving Party can clearly demonstrate: was known to the receiving Party prior to disclosure; or was or becomes part of the public domain through no fault of the receiving Party; or becomes lawfully available to the receiving Party by an unconnected third party who is under no obligation of confidentiality in respect thereof, or with the lawful right to make such disclosure; or has been independently developed or conceived by it; or it is required to disclose by law.
Confidentiality and Publications. 7.01 In the performance of this Agreement, each Party may disclose directly or indirectly to the other party certain confidential information, orally or in writing or both, including, but not be limited to, marketing plans, cost or price data, customer or supplier information, technical information, patent applications, and patent prosecution documents regarding the Accelr8 Technology or the Licensed Product (collectively, “Confidential Information”). Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the disclosing Party, the Parties agree that, during the Term for at least five (5) years and thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any Confidential Information. A Party may use such Confidential Information only to the extent required to accomplish the purposes of this Agreement. Neither Party will use any Confidential Information of any other Party for any purpose or in any manner that would constitute a violation of any laws or regulations, including, without limitation, the export control laws of the United States. Neither Party may reproduce any Confidential Information of any other Party in any form except as required to accomplish the intent of this Agreement. Neither Party may disclose Confidential Information of any other Party to any employee, agent, consultant, or sublicensee who does not have a reasonable need for such information for purposes of performance under this Agreement and who is not subject to binding obligations of confidentiality and limited use at least as restrictive as those of this Article 8. In particular, neither Party will disclose to a Third Party any legal opinions with regard to Accelr8’s Intellectual Property without first obtaining a “Community of Interest” agreement from such Third Party that includes Accelr8 as named in the Community of Interest. Each Party will use at least the same standard of care as it uses to protect its own proprietary or confidential information of a similar nature to prevent unauthorized disclosures or uses of Confidential Information of the other Party, but in no event less than reasonable care. Each Party will promptly notify the disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party.
Confidentiality and Publications. 3.1 The RECIPIENT agrees to keep reserved all information received from the PROVIDER that are marked as "Confidential Information" and agrees to make reasonable efforts to prevent disclosure, with the exception of its employees who are bound by this Agreement. The oral communication made by the PROVIDER to the RECIPIENT must be qualified as confidential by the PROVIDER in a written communication within 10 days from the oral communication.
Confidentiality and Publications. 4.1 All Research Materials and Data are subject to the confidentiality provisions set forth in the InterTau Agreements.
Confidentiality and Publications. (1) Each party may xxxx any written information confidential. ANADYS TECHNOLOGY LICENSE AGREEMENT
Confidentiality and Publications. 6.1 Unless otherwise provided for in this Agreement, both parties shall treat the Know-How and any and all other information and data received or derived under this Agreement as strictly confidential, and shall not disclose the same to any Third Party during the Agreement Period and for five years thereafter, except for information which:
Confidentiality and Publications. A. Consultant acknowledges that prior to and during the term of this Agreement Consultant has had and will have access to confidential and proprietary information relating to Mytogen's myoblast product, Mytogen's hemangioblast product and Mytogen's cardio-myocyte program (if any) belonging to Mytogen ("Confidential Information"). Confidential Information shall include, but is not limited to, any scientific, technical, trade or business information possessed, obtained by, developed for or given to Consultant relating to Mytogen's myoblast product, Mytogen's hemangioblast product and Mytogen's cardio-myocyte program (if any) which is treated by Mytogen as confidential or proprietary including, without limitation, Work Product, research materials (including without limitation test articles, test substances, medical devices, chemical compounds or other materials such as biologicals, including, without limitation, genes, DNA sequences, plasmids, vectors, expression systems, cells, cell lines, organisms, antibodies, biological substances, and any constituents, progeny, mutants, derivatives or replications thereof or therefrom, together with all reagents, chemical compounds or other materials), formulations, techniques, methodology, assay systems, formulae, procedures, tests, equipment, data, reports, know-how, sources of supply, patent positioning, patent applications, relationships with consultants and employees, business plans and business developments, information concerning the existence, scope or activities of any research, development, manufacturing, marketing or other projects of Mytogen relating to Mytogen's myoblast product, Mytogen's hemangioblast product and Mytogen's cardio-myocyte program (if any), all copies, digests, summaries, extracts or the like of the Confidential Information, as well as feedback, suggestions, improvements or other inventions, ideas or works of authorship derived from the Confidential Information, and any other confidential or proprietary information about or belonging to Mytogen's suppliers, licensors, licensees, partners, collaborators, affiliates, customers, potential customers or others relating to Mytogen's myoblast product, Mytogen's hemangioblast product and Mytogen's cardio-myocyte program (if any).
